WDC Leads €2m Investement In Biotechnology Company Ovagen
The Western Development Commission has led a €2 million Series A equity investment round in Ovagen Group Limited, a biotechnology company based in Ballina, Co Mayo. The funding is aimed at accelerating the production of Ovagen’s germ-free eggs. Read the full article: https://lnkd.in/dxs86DUa Enterprise Ireland HBAN Boole Investments DeepIE Ventures Spark Crowdfunding Photo credit: Michael … Continue reading WDC Leads €2m Investement In Biotechnology Company Ovagen
11th Annual Avian Model Systems Conference at the University of Plymouth
Ovagen Group Limited recently attended the 11th Annual Avian Model Systems Conference at the University of Plymouth, UK (11-14SEP2023). It was a wonderful four days of fantastic avian research presentations ranging from developmental biology and evolution to immunology, novel techniques, and the application of avian models in biomedical research, diagnostics, and vaccine production. The plenary … Continue reading 11th Annual Avian Model Systems Conference at the University of Plymouth
We Are Hiring – Production Technician
Who We Are – Ovagen Group Limited We are an innovation based biotechnology company that has developed a proprietary process of producing the world’s first Germ Free eggs, for use in vaccine manufacture and other pharmaceutical and research applications. Germ free eggs are the highest quality products available to produce medicines like vaccines, reducing contamination and … Continue reading We Are Hiring – Production Technician
HBAN leads €1.1M investment in Mayo biotech company, Ovagen Group Ltd
Ballina, Mayo, 3rd February, 2023 – HBAN (Halo Business Angel Network), the all-island organisation responsible for the promotion of business angel investment, and a joint initiative of Enterprise Ireland and InterTradeIreland, today announces that its syndicates, Irrus Investments and WxNW, have led a €1.1M oversubscribed funding round in Ovagen, the world’s first producer of germ-free … Continue reading HBAN leads €1.1M investment in Mayo biotech company, Ovagen Group Ltd
EU Funding Enables Ovagen to Tackle Global Vaccine Market
*THE FOLLOWING ARTICLE WAS POSTED ON HORIZON EUROPE WEBSITE ON DECEMBER 6TH 2022* TO LINK TO THE ORIGINAL ARTICLE PLEASE CLICK HERE Vaccine manufacturing has never been more to the forefront of the news than in recent years. With everyone acutely aware of how vital vaccines are, Irish biotech firm Ovagen Group Ltd. has good news. With … Continue reading EU Funding Enables Ovagen to Tackle Global Vaccine Market
We are Hiring – Microbiology Lead
Who We Are – Ovagen Group Limited We are an innovation based biotechnology company that has developed a proprietary process of producing the world’s first Germ Free eggs, for use in vaccine manufacture and other pharmaceutical and research applications. Germ free eggs are the highest quality products available to produce medicines like vaccines, reducing contamination … Continue reading We are Hiring – Microbiology Lead
Ovagen Group Limited secures €10 million funding award from EIC Accelerator fund.
FOR IMMEDIATE RELEASE Second time in 3 years Ballina-based company has received EIC Accelerator funding Follows the announcement of developing the world’s first bacteria free (‘germfree’) eggs in April. Positions Ovagen as a potential world-leader in the production of germ-free eggs, 22nd June 2022, Ballina, Mayo, Ireland – Biotechnology company Ovagen Group Limited has again … Continue reading Ovagen Group Limited secures €10 million funding award from EIC Accelerator fund.
Ovagen Receives a Second European Innovation Council (EIC) Grant
On 17th June 2022 Ovagen Group Ltd. was selected by the European Commission for €10M in grant and equity funding in what was the most competitive round of European Innovation Council (EIC) Accelerator funding to date, with only 7% of the over 1,000 companies across Europe being funded. This is the second time Ovagen has … Continue reading Ovagen Receives a Second European Innovation Council (EIC) Grant
Ovagen Group Limited Announce the Launch of the World’s First Germ-Free Egg
This innovative and disruptive technology will set a new ‘gold standard in the market’ eliminating bacterial contamination and potential for increased viral yield in egg based vaccine manufacture This ground-breaking development will support the manufacturing of vaccines and scientific research These bacteria, or ‘germfree’, eggs will be available for commercial sale in Q2 this year … Continue reading Ovagen Group Limited Announce the Launch of the World’s First Germ-Free Egg
Customer Endorsements
“We produce influenza vaccine, we currently use SPF eggs for production of viral seed material. We find bacterial contaminants within these SPF eggs. This can have a big impact on our production schedules. I would be interested in exploring the use of your 100% bacterial free eggs”
Process Scientific Expert, Influenza Vaccine Manufacturer
“We still encounter a failure rate through contamination of up to 20%. One contaminated egg ruins an entire batch which has obvious cost implications for the company. We would be prepared to pay a premium price for superior quality eggs from Ovagen, which would offset the cost of contamination”
President, Infectious Diseases Vaccine Manufacturer